Recce Pharmaceuticals Appoints Alistair McKeough to its Board of Directors
September 07, 2022 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company) is pleased to announce the appointment of Alistair McKeough to its Board of...
Recce Pharmaceuticals Announces Positive Safety Data from Seventh Cohort of Phase 1 Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
August 23, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: 10 subjects in cohort seven were intravenously dosed with RECCE® 327 at 6,000mg Independent Safety Committee reviewing cohort seven data and anticipate a recommendation to proceed to...
Recce Pharmaceuticals Appoints Philip Sutton, Ph.D., as Vice President of Translational Sciences
July 12, 2022 08:00 ET
|
Recce Pharmaceuticals
– Dr. Sutton to help advance Recce’s portfolio of infectious disease programs focused on significant unmet medical needs – SYDNEY Australia, July 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals...
Recce Pharmaceuticals Announces Positive Safety Data from Sixth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
June 22, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: 10 subjects in cohort six intravenously dosed with RECCE® 327 at 4,000mg demonstrated good safety and tolerabilityIndependent Safety Committee to review cohort six data – anticipate...
Recce Pharmaceuticals Announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE® 327 and Initiates Sixth Cohort at 4,000mg
May 23, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: In cohort five, RECCE® 327 (R327) demonstrated good safety and tolerability in subjects intravenously dosed at 2,000mgIndependent Safety Committee approves cohort six dosing at 4,000mg;...
Recce Pharmaceuticals Announces Phase I Clinical Trial of RECCE® 327 Advances to High Dosing Level
April 13, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: 36 subjects successfully dosed in Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) – demonstrating good safety and tolerability at 1,000mg Independent Safety Committee...
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives
April 12, 2022 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, April 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...
Recce Pharmaceuticals Announces Positive Safety Data from Fourth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
March 30, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: 10 subjects in cohort four intravenously dosed; RECCE® 327 at 1,000mg, indicating to be safe and well-tolerated Independent Safety Committee to review cohort four data – expect...
Recce Pharmaceuticals Receives Research and Development (R&D) Incentive Rebate
March 29, 2022 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, March 29, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to...
Recce Pharmaceuticals Announces Safety Committee Clears Next Dose in Phase I Study of RECCE® 327
March 08, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: Independent Safety Committee unanimously recommends cohort four (RECCE® 327 at 1,000mg) to commence; a 20-fold increase from cohort one dose (50mg)Cohort four subjects recruited - RECCE®...